0 421

Cited 117 times in

Perforation in colorectal stenting: a meta-analysis and a search for risk factors.

Authors
 Emo E. van Halsema  ;  Jeanin E. van Hooft  ;  Aaron J. Small  ;  Todd H. Baron  ;  Jesús García-Cano  ;  Jae Hee Cheon  ;  Moon Sung Lee  ;  Se Hwan Kwon  ;  Stéphanie Mucci-Hennekinne  ;  Paul Fockens  ;  Marcel G.W. Dijkgraaf  ;  Alessandro Repici 
Citation
 GASTROINTESTINAL ENDOSCOPY, Vol.79(6) : 970-982, 2014 
Journal Title
GASTROINTESTINAL ENDOSCOPY
ISSN
 0016-5107 
Issue Date
2014
MeSH
Colon/injuries* ; Colonic Diseases/surgery* ; Global Health ; Humans ; Incidence ; Intestinal Obstruction/surgery* ; Intestinal Perforation*/diagnosis ; Intestinal Perforation*/epidemiology ; Intestinal Perforation*/etiology ; Intraoperative Complications* ; Risk Assessment/methods* ; Risk Factors ; Stents/adverse effects*
Abstract
BACKGROUND: Recent studies suggest that there is a substantial risk of perforation after colorectal stent placement.
OBJECTIVE: To identify risk factors for perforation from colonic stenting.
DESIGN: A meta-analysis of 86 studies published between 2005 and 2011.
SETTING: Multicenter review.
PATIENTS: All patients who underwent colorectal stent placement.
INTERVENTION: Colorectal stent placement.
MAIN OUTCOME MEASUREMENTS: The occurrence of perforation with subgroup analyses for stent design, stricture etiology, stricture dilation, and concomitant chemotherapy, including the use of bevacizumab.
RESULTS: A total of 4086 patients underwent colorectal stent placement; perforation occurred in 207. Meta-analysis revealed an overall perforation rate of 7.4%. Of the 9 most frequently used stent types, the WallFlex, the Comvi, and the Niti-S D-type had a higher perforation rate (>10%). A lower perforation rate (<5%) was found for the Hanarostent and the Niti-S covered stent. Stenting benign strictures was associated with a significantly increased perforation rate of 18.4% compared with 7.5% for malignant strictures. Dilation did not increase the risk of perforation: 8.5% versus 8.5% without dilation. The subgroup of post-stent placement dilation had a significantly increased perforation risk of 20.4%. With a perforation rate of 12.5%, bevacizumab-based therapy was identified as a risk factor for perforation, whereas the risk for chemotherapy without bevacizumab was 7.0% and not increased compared with the group without concomitant therapies during stent therapy (9.0%).
LIMITATIONS: Heterogeneity; a considerable proportion of data is unavailable for subgroup analysis.
CONCLUSIONS: The perforation rate of colonic stenting is 7.4%. Stent design, benign etiology, and bevacizumab were identified as risk factors for perforation. Intraprocedural stricture dilation and concomitant chemotherapy were not associated with an increased risk of perforation.
Full Text
http://www.sciencedirect.com/science/article/pii/S0016510713026345
DOI
10.1016/j.gie.2013.11.038
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Cheon, Jae Hee(천재희) ORCID logo https://orcid.org/0000-0002-2282-8904
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/138376
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links